For the Inventor, By the Inventor

Enter assignee name

Philadelphia, PA, United States of America

Smithkline Beckman Corporation

Calculating rank

USPTO Granted Patents = 207

Trademarks = 3

Forward Citations = 1,803

Loading Chart...

Loading Chart...

167 inventors (with patents filed for the assignee):

Lawrence I Kruse (28 out of 45 patents)

Carl Kaiser (19 out of 46 patents)

William F Huffman (19 out of 47 patents)

4. Michael L Moore (14 out of 20 patents)

5. Joseph Weinstock (14 out of 65 patents)

6. Nelson C Yim (13 out of 20 patents)

7. David T Hill (13 out of 43 patents)

8. Paul E Bender (10 out of 44 patents)

9. John G Gleason (10 out of 66 patents)

10. Stephen T Ross (10 out of 21 patents)

11. Randall K Johnson (9 out of 19 patents)

12. Robert M DeMarinis (9 out of 35 patents)

13. Fadia E Ali (9 out of 19 patents)

14. James Francis Callahan (8 out of 64 patents)

15. Robert D Sitrin (7 out of 11 patents)

Core Competencies:

Dopamine-Beta-Hydroxylase

Inhibitors

Leukotriene Antagonists

Tumor Cell Growth

Pharmaceutical Compositions

Protein Protease Inhibitors

Vasopressin Compounds

Epoxy Esters

Immunomodulation

Antitumor Compounds

Growth Hormone Analogs

207 patents: Sort by Forward Citations

1. 5498529 - Protein protease inhibitors from streptomyces (1996-03-12),

2. 5422274 - Internal deletion mutants of soluble T4(CD4) (1995-06-06),

3. 5356877 - Methods for promoting growth using porcine growth hormone analogs (1994-10-18),

4. 5110959 - Process for preparation of epoxy esters and intermediates prepared (1992-05-05),

5. 5110906 - Derivatives of soluble T-4 (1992-05-05),

6. 5037812 - Tumor cell growth-inhibiting pharmaceutical compositions containing (1991-08-06),

7. 5008390 - Compounds for preparing 6-phenyl-2,3-dihydroimidazo[2,1-b]-thiazoles and (1991-04-16),

8. 4937237 - Phosphinic acid substituted aromatic steroids as inhibitors of steroid (1990-06-26),

9. 4935438 - Dopamine-.beta.-hydroxylase inhibitors (1990-06-19),

10. 4912226 - Intermediate to dopamine-.beta.-hydroxylase inhibitors (1990-03-27),

11. 4910226 - Steroid 5-alpha-reductase inhibitors (1990-03-20),

12. 4908475 - Intermediates for preparing 1,6-dicarba-vasopressin compounds (1990-03-13),

13. D306347 - Delayed action dosage unit for releasing medicaments or the like in (1990-02-27),

14. 4902675 - '2-pyridyl and 4-pyridyl phosphine gold (I) anti tumor complexes' (1990-02-20),

15. 4888336 - Steroid 5-alpha-reductase inhibitors (1989-12-19),

Company Overview

Smithkline Beckman Corporation, based in Philadelphia, PA, specializes in the development and manufacturing of pharmaceutical products, particularly focusing on dopamine inhibitors. The company is engaged in advanced research related to dopamine-beta-hydroxylase, leukotriene antagonists, and protein protease inhibitors, among other core technology topics. Its innovative approach aims to address various health challenges, including tumor cell growth and vasopressin-related conditions, contributing significantly to the pharmaceutical landscape.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 27 2026

207 Patents

#14 in Philadelphia, PA

#87 in Pennsylvania

#2,005 in US

#4,114 in the World

Philadelphia, PA, United States of America

Smithkline Beckman Corporation

Forward Citations = 1,803

167 inventors:

Lawrence I Kruse (28 out of 45 patents)

Carl Kaiser (19 out of 46 patents)

William F Huffman (19 out of 47 patents)

4. Michael L Moore (14 out of 20 patents)

5. Joseph Weinstock (14 out of 65 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Smithkline Beckman Corporation. Retrieved from https://idiyas.com/company/smithkline-beckman

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…